Literature DB >> 9388270

Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.

B Dufourny1, J Alblas, H A van Teeffelen, F M van Schaik, B van der Burg, P H Steenbergh, J S Sussenbach.   

Abstract

Addition of insulin-like growth factor I (IGF-I) to quiescent breast tumor-derived MCF-7 cells causes stimulation of cyclin D1 synthesis, hyperphosphorylation of the retinoblastoma protein pRb, DNA synthesis, and cell division. All of these effects are independent of the mitogen-activated protein kinase (MAPK) pathway since none of them is blocked by PD098059, the specific inhibitor of the MAPK activating kinase MEK1. This observation is consistent with the finding that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a strong inducer of MAPK activity in MCF-7 cells, effectively inhibits proliferation. The anti-proliferative effect of TPA in these cells may be accounted for, at least in part, by the MAPK-dependent stimulation of the synthesis of p21(WAF1/CIP1), an inhibitor of cyclin/cyclin-dependent kinase complexes. In contrast, all of the observed stimulatory effects of IGF-I on cell cycle progression, cyclin D1 synthesis, and pRb hyperphosphorylation were blocked by the specific phosphatidylinositol 3-kinase inhibitor LY294002, suggesting that phosphatidylinositol 3-kinase activity but not MAPK activity is required for transduction of the mitogenic IGF-I signal in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9388270     DOI: 10.1074/jbc.272.49.31163

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.

Authors:  G Castoria; M V Barone; M Di Domenico; A Bilancio; D Ametrano; A Migliaccio; F Auricchio
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells.

Authors:  Simona Caporali; Manami Imai; Lucia Altucci; Massimo Cancemi; Silvana Caristi; Luigi Cicatiello; Filomena Matarese; Roberta Penta; Dipak K Sarkar; Francesco Bresciani; Alessandro Weisz
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

3.  An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Authors:  Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland
Journal:  Breast Cancer Res Treat       Date:  2006-06-05       Impact factor: 4.872

Review 4.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

5.  Insulin like growth factor 2 regulation of aryl hydrocarbon receptor in MCF-7 breast cancer cells.

Authors:  Justin K Tomblin; Travis B Salisbury
Journal:  Biochem Biophys Res Commun       Date:  2013-12-28       Impact factor: 3.575

6.  Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.

Authors:  Paolo A Zucali; Iacopo Petrini; Elena Lorenzi; Maria Merino; Liang Cao; Luca Di Tommaso; Hye Seung Lee; Matteo Incarbone; Beatriz A Walter; Matteo Simonelli; Massimo Roncalli; Armando Santoro; Giuseppe Giaccone
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

Review 7.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

8.  ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xin-Tian Zhang; Ju Yuan; Mo Li; Jie Qiao; Zhao-Yi Wang; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

9.  The insulin-like growth factor system and its receptors: A potential novel anticancer target.

Authors:  Colin R Lindsay; Tr Jeffry Evans
Journal:  Biologics       Date:  2008-12

10.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Authors:  B L Smith; D Chin; W Maltzman; K Crosby; G N Hortobagyi; S S Bacus
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.